Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury

• Type of Material: Article
• Authors: Joshua K Wong, University of Florida; Günther Deuschl, University of Kiel; Robin Wolke, University of Kiel; Hagai Bergman, Hebrew University of Jerusalem; Muthuraman Muthuraman, Johannes Gutenberg University of Mainz; Sergiu Groppa, Johannes Gutenberg University of Mainz; Sameer A Sheth, Baylor College of Medicine; Helen M Bronte-Stewart, Stanford University; Kevin B Wilkins, Stanford University; Matthew N Petrucci, Stanford University; Emilia Lambert, Stanford University; Yasmine Kehnemouyi, Stanford University; Philip A Starr, University of California San Francisco; Simon Little, University of California San Francisco; Juan Anso, University of California San Francisco; Ro’ee Gilron, University of California San Francisco; Lawrence Poree, University of California San Francisco; Giridhar P Kalamangalam, University of Florida; Gregory A Worrell, Mayo Clinic, Rochester; Kai J Miller, Mayo Clinic, Rochester; Nicholas D Schiff, Weill Cornell Medicine; Christopher R Butson, University of Florida; Jaimie M Henderson, Stanford University; Jack W Judy, University of Florida; Adolfo Ramirez-Zamora, University of Florida; Kelly D Foote, University of Florida; Peter A Silburn, University of Queensland; Luming Li, Tsinghua University; Genko Oyama, Juntendo University; Hikaru Kamo, Juntendo University; Satoko Sekimoto, Juntendo University; Nobutaka Hattori, Juntendo University; James J Giordano, Georgetown University Medical Center; Diane DiEuliis, National Defense University, Washington; John R Shook, University of Buffalo; Darin D Doughtery, Massachusetts General Hospital; Alik S Widge, University of Minnesota, Minneapolis; Helen Mayberg, Emory University; Jungho Cha, Icahn School of Medicine at Mount Sinai; Kisueng Choi, Icahn School of Medicine at Mount Sinai; Stephen Heisig, Icahn School of Medicine at Mount Sinai; Mosadolu Obatusin, Icahn School of Medicine at Mount Sinai; Enrico Opri, Emory University; Scott B Kaufman, Columbia University; Prasad Shirvalkar, Stanford University; Christopher J Rozell, Georgia Institute of Technology; Sankaraleengam Alagapan, Georgia Institute of Technology; Robert S Raike, Medtronic Inc; Hemant Bokil, Boston Sci Neuromodulat Corp; David Green, NeuroPace Inc; Michael S Okun, University of Florida
• Language: English
• Date: 2022-03-04
• Publisher: FRONTIERS MEDIA SA
• Publication Version: Final Published Version
• Copyright Statement: © 2022 Wong, Deuschl, Wolke, Bergman, Muthuraman, Groppa, Sheth, Bronte-Stewart, Wilkins, Petrucci, Lambert, Kehnemouyi, Starr, Little, Anso, Gilron, Poree, Kalamangalam, Worrell, Miller, Schiff, Butson, Henderson, Judy, Ramirez-Zamora, Foote, Silburn, Li, Oyama, Kamo, Sekimoto, Hattori, Giordano, DiEuliis, Shook, Doughtery, Widge, Mayberg, Cha, Choi, Heisig, Obatusin, Opri, Kaufman, Shirvalkar, Rozell, Alagapan, Raike, Bokil, Green and Okun.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.3389/fnhum.2022.813387
• Title of Journal or Parent Work: FRONTIERS IN HUMAN NEUROSCIENCE
• Volume: 16
• Start Page: 813387
• End Page: 813387
• Grant/Funding Information: JH also received hardware support from Medtronic for the study described in this article. JJ has received research grants from the Michael J. Fox Foundation. DDD received research support and honoraria from Medtronic. HM received grant support from NIH UH3NS103550, 2R01MH102238, and the Hope for Depression Research Foundation, and consulting and licensing fees from Abbott Labs.; CB holds intellectual property related to some of the results presented. CB has served as a consultant for NeuroPace, Advanced Bionics, Boston Scientific, IntelectMedical, Abbott (St. Jude Medical), Functional Neuromodulation, NeuraModix. JH served on the advisory board for Enspire DBS, a consultant for Neuralink and received research support from Boston Scientific; PSh received research support from Medtronic but not financial support.; JW’s research was supported by NIH R25NS108939. SAS was a consultant for Boston Scientific, Abbott, Zimmer Biomet, and Neuropace. SAS was also funded by NIH UH3 NS103549, the McNair Foundation, and the Dana Foundation. HB-S served on the Clinical Advisory Board for Medtronic. PAS received research support and fellowship training support from Medtronic. NS was a member of the scientific advisory board for EnspireDBS, Inc. and QuantalX, Inc. NS also received current grant funding from the BRAIN Initiative, National Institute of Neurological Disorders and Stroke, and the James S. McDonnell Foundation.; MSO served as a consultant for the Parkinson’s Foundation, and has received research grants from NIH, Parkinson’s Foundation, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. MSO’s DBS research was supported by: NIH R01 NR014852 and R01NS096008. MSO was PI of the NIH R25NS108939 Training Grant.
• Keywords: Psychology; PARKINSONS-DISEASE; Life Sciences & Biomedicine; pain; epilepsy; traumatic brain injury; artificial intelligence; interventional psychiatry; Social Sciences; RESPONSIVE NEUROSTIMULATION; NUCLEUS; THALAMIC-STIMULATION; deep brain stimulation; SURGERY; ESSENTIAL TREMOR; Neurosciences & Neurology; Science & Technology; adaptive DBS; neuroethics; Neurosciences; SEIZURE OUTCOMES
• Research Categories: Health Sciences, Mental Health; Health Sciences, Medicine and Surgery

Abstract

DBS Think Tank IX was held on August 25–27, 2021 in Orlando FL with US based participants largely in person and overseas participants joining by video conferencing technology. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging deep brain stimulation (DBS) technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank IX speakers was that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. After collectively sharing our experiences, it was estimated that globally more than 230,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. As such, this year’s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia and Australia; cutting-edge technologies, neuroethics, interventional psychiatry, adaptive DBS, neuromodulation for pain, network neuromodulation for epilepsy and neuromodulation for traumatic brain injury.